Compare Open Text Corporation (OTEX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Open Text Corporation trades at $24.96 (market cap $6.02B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Open Text Corporation pays a 4.49% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Open Text Corporation for 24 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OTEX | SYRE | |
|---|---|---|
Market Cap | $6.02B | $7.52B |
Volume | 1,820,095 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $39.69 | $108.92 |
52-Week Low | $20.01 | $22.18 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.03B | $6.52B |
Dividend Yield | 4.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OpenText (OTEX) trades at $24.95, up 3.18% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with a P/E of 9.67, robust 73.74% gross margins, and consistent earnings beats in recent quarters. Recent debt restructuring activities and strategic AI partnerships with Cohere highlight management's focus on growth optimization and technological advancement.
The outlook remains positive with a consensus price target of $28.30 offering 13% upside potential. Key risks include high debt levels and competitive pressures in the enterprise software sector. Analyst sentiment leans bullish with 42% buy ratings, though the stock faces near-term resistance at the $25 level.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
